PDCD1 and neoplasm: As shown in Figure 4I,J, the FS and EF were significantly decreased in the anti-PD-1 treated-tumor group compared to IgG-treated tumor group (FS = 22.62% versus 28.42%, (p < 0.05); EF = 44.58% versus 53.36%, (p < 0.05)).